INDIAN BIOPHARMA INDUSTRY GROWING AT 12% CROSSES Rs.22,000 CRORE
The Indian Biopharma Industry with over 300 300 companies is growing at 12 per cent growth against the pharma industry growth which is passing through tough situation post-GST, ban on manufacture, sale and distribution of over 340 fixed dose combination (FDC) drugs. For the year 2018-19 the Biopharma Industry crossed Ps 22,124 crore over previous year's revenue of Ps 18,290 core with exports comprising of Ps 14,423 crore in 2018-19 witnessing growth over last year's exports of 13,925 crore.
Indian Biopharma industry, comprising hormones, insulin, blood products and vaccines also imported biopharma products worth Ps 5500 core in 2018-19 as against previous year's imports of Ps 5039 crore.
Serum Institute of India Ltd continues to lead the Indian biopharmaceutical industry with a revenue of Ps 4984 crore followed by Biocon (Ps 3946 crore) and Novo Nordisk with Ps 1352 crore. Top 3 biopharma companies contribute to 46 per cent of the total biopharma industry of Ps 22,145 crore. And Top 20 biopharma companies contribute to 89 per cent of the total biopharma industry.
Western region continues to dominate the biopharma industry with contribution of 59 per cent followed by Southern region with 36 per cent and remaining 4 per cent coming from Northern region. Indian biopharma companies exported Ps 8100 crore worth hormones and related products during 2018-19 against Ps 7963 crore worth of products in 2017-18. Vaccines worth Ps 4453 crore were exported in 2018-19.
According to AIOCD Pharmasofttech AWACS Pvt. Ltd, there are over 200 companies in blood related products. Pfizer is leading the market in the country with sales of Ps 150 crore in 2018-19. Abbott India is leading the hormones market in India with Ps 349 crore in 2018-19. In the hormones space too there are about 200 companies in the business. Only in insulin and vaccines space the number of companies are less than 20 and 40 respectively. GlaxoSmithKline Pharmaceuticals Ltd. is leading the vaccines business in the country (out of pocket) with sales of Ps 662 core. Novo Nordisk India Pvt Ltd continues to lead the insulin market with Ps 1351 crore. In all these biological segments the domestic market is being led by multinational companies. However Indian companies do have some presence but still they need to do a lot to come at par with the multinational companies.